We are pleased to share the latest in-vivo results from our ongoing research together with Bioton into our innovative transdermal insulin delivery system. Our MTC-Y technology continues to demonstrate encouraging performance when compared to traditional subcutaneous insulin administration.
Study Design
Our comparative study utilized:
- Insulin SC (Gensulin N – 0.035 mg/animal)
- Transdermal MTC Carrier (insulin – 0.36 mg/animal)
We employed male Sprague Dawley rats as the animal model, measuring plasma insulin levels using the ELISA method. Our objective was to compare insulin plasma concentrations following subcutaneous and our transdermal administration.
RESULTS
Key Findings
- Bioavailability: Our transdermal insulin administration (MTC-I) achieved a bioavailability of 55.1%.
- Sustained Release: Our MTC-I demonstrated a more sustained release profile compared to subcutaneous administration (SC), maintaining higher concentration levels for a longer duration.
- Extended Effect: A single application of our transdermal system sustained therapeutic concentrations for up to 5 days, potentially offering a significant advantage in dosing frequency.
These results reinforce our confidence in the potential of our MTC-I technology to provide an effective alternative to traditional insulin delivery methods. We believe our approach could offer patients a more convenient option for diabetes management, potentially improving treatment adherence and quality of life.
We continue to advance our research and look forward to sharing more updates as we progress towards our goal of revolutionizing insulin delivery for diabetes patients.